Redburn lifts Abbott Laboratories [ABT] price estimate. Who else is bullish?



Abbott Laboratories [NYSE: ABT] stock went on an upward path that rose over 1.34% on Friday, amounting to a one-week price increase of more than 7.86%. The company report on October 20, 2021 that Abbott Reports Third-Quarter 2021 Results; Achieves Strong Double-Digit Earnings Growth and Raises Guidance.

– Third-quarter sales growth of 23.4 percent; organic sales growth of 22.4 percent.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free


– GAAP diluted EPS from continuing operations growth of 69.6 percent; adjusted diluted EPS growth of 42.9 percent.

Over the last 12 months, ABT stock rose by 15.75%. The one-year Abbott Laboratories stock forecast points to a potential upside of 4.2. The average equity rating for ABT stock is currently 2.00, trading closer to a bullish pattern in the stock market.

The market cap for the stock reached $224.80 billion, with 1.78 billion shares outstanding and 1.76 billion shares in the current float. Compared to the average trading volume of 4.68M shares, ABT stock reached a trading volume of 5715717 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Guru’s Opinion on Abbott Laboratories [ABT]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ABT shares is $132.28 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ABT stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Redburn have made an estimate for Abbott Laboratories shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on October 14, 2021. While these analysts kept the previous recommendation, Barclays raised their target price to Overweight. The new note on the price target was released on May 25, 2021, representing the official price target for Abbott Laboratories stock. Previously, the target price had yet another raise to $122, while Atlantic Equities analysts kept a Neutral rating on ABT stock.

The Average True Range (ATR) for Abbott Laboratories is set at 2.22, with the Price to Sales ratio for ABT stock in the period of the last 12 months amounting to 5.59. The Price to Book ratio for the last quarter was 6.67, with the Price to Cash per share for the same quarter was set at 5.04. Price to Free Cash Flow for ABT in the course of the last twelve months was 39.02 with Quick ratio for the last quarter at 1.40.

ABT Stock Performance Analysis:

Abbott Laboratories [ABT] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 7.86. With this latest performance, ABT shares gained by 1.13% in over the last four-week period, additionally plugging by 3.38% over the last 6 months – not to mention a rise of 15.75% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ABT stock in for the last two-week period is set at 67.76, with the RSI for the last a single of trading hit 77.23, and the three-weeks RSI is set at 62.30 for Abbott Laboratories [ABT]. The present Moving Average for the last 50 days of trading for this stock 123.25, while it was recorded at 122.25 for the last single week of trading, and 119.46 for the last 200 days.

Insight into Abbott Laboratories Fundamentals:

Operating Margin for any stock indicates how profitable investing would be, and Abbott Laboratories [ABT] shares currently have an operating margin of +15.29 and a Gross Margin at +50.21. Abbott Laboratories’s Net Margin is presently recorded at +12.86.

Return on Total Capital for ABT is now 10.24, given the latest momentum, and Return on Invested Capital for the company is 8.83. Return on Equity for this stock inclined to 13.93, with Return on Assets sitting at 6.34. When it comes to the capital structure of this company, Abbott Laboratories [ABT] has a Total Debt to Total Equity ratio set at 60.67. Additionally, ABT Total Debt to Total Capital is recorded at 37.76, with Total Debt to Total Assets ending up at 27.42. Long-Term Debt to Equity for the company is recorded at 59.26, with the Long-Term Debt to Total Capital now at 36.89.

Reflecting on the efficiency of the workforce at the company, Abbott Laboratories [ABT] managed to generate an average of $40,817 per employee. Receivables Turnover for the company is 5.85 with a Total Asset Turnover recorded at a value of 0.49.Abbott Laboratories’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.40 and a Current Ratio set at 1.80.


The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ABT. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Abbott Laboratories go to 12.53%.

Abbott Laboratories [ABT] Insider Position Details

There are presently around $166,524 million, or 75.40% of ABT stock, in the hands of institutional investors. The top three institutional holders of ABT stocks are: VANGUARD GROUP INC with ownership of 147,844,584, which is approximately 0.871% of the company’s market cap and around 0.70% of the total institutional ownership; BLACKROCK INC., holding 132,190,774 shares of the stock with an approximate value of $16.75 billion in ABT stocks shares; and CAPITAL RESEARCH GLOBAL INVESTORS, currently with $10.88 billion in ABT stock with ownership of nearly 0.034% of the company’s market capitalization.

>> 7 Top Picks for the Post-Pandemic Economy <<

Positions in Abbott Laboratories stocks held by institutional investors increased at the end of October and at the time of the October reporting period, where 1,167 institutional holders increased their position in Abbott Laboratories [NYSE:ABT] by around 56,937,032 shares. Additionally, 1,047 investors decreased positions by around 62,554,182 shares, while 388 investors held positions by with 1,194,619,922 shares. The mentioned changes placed institutional holdings at 1,314,111,136 shares, according to the latest SEC report filing. ABT stock had 125 new institutional investments in for a total of 6,464,101 shares, while 109 institutional investors sold positions of 5,522,046 shares during the same period.



Download Free eBook For


100% free. stop anytime no spam



Download Free eBook For


100% free. stop anytime no spam